Boston, Massachusetts


The purpose of this study is to study the impact of gut bacteria on weight. Fecal microbiota transplantation (FMT) transfers intestinal bacteria by a "stool transplant" from a healthy, lean person to a person with obesity.

Study summary:

Multiple lines of evidence suggest that gut microbiota play an important role in regulating human metabolism. In this study, subjects will receive FMT capsules from lean metabolically healthy donors to study effects on body weight and insulin sensitivity. Subjects who participate will be randomized 1:1 to receive either active FMT capsules or placebo capsules. Subjects and providers will be blinded to treatment assignment. The study will last for 24 weeks. Subjects will be asked to come to MGH for a baseline visit at week 0, return for 6 weekly visits and come back at week 12. Major study outcomes include change in weight, insulin sensitivity, and body composition. Fecal samples will also be collected for intestinal microbiome analysis.


Inclusion Criteria: - BMI ≥30 kg/m2 - Because of frequent study mandated visits, only subjects living within reasonable driving distance of Massachusetts General Hospital may be enrolled Exclusion Criteria: - Pregnant women - Use of diabetic medications or weight loss medications in the preceding 1 year - Significant gastrointestinal disorders - Significant food allergies - Immunosuppressed patients



Primary Contact:

Petr Stastka, BS
Phone: 617-643-7951

Backup Contact:

Jasmin Mahabamunuge, BA
Phone: 617-724-8625

Location Contact:

Boston, Massachusetts
United States

Petr Stastka, BS

Site Status: Recruiting

Data Source:

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.